Methods and compositions for reducing risk of relapse and prolonging survival in acute myeloid leukemia

Abstract

Some embodiments provided herein relate to methods and compositions for reducing the risk of relapse of a hyperproliferative disorder, such as acute myeloid leukemia (AML), in a subject in which the hyperproliferative cells of the subject exhibit a normal karyotype and / or in a subject who has been administered no more than one induction therapeutic course. Some such embodiments include the administration of a NOX2 inhibitor, such as histamine dihydrochloride (HDC), in combination with a cytokine, such as interleukin-2 (IL-2).

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Prov. App. No. 62 / 662,246, filed April 25, 2018, entitled "NOX2INHIBITORS AND LOW-DOSE INTERLEUKIN-2FOR TREATING ACUTE MYELOID LEUKEMIA WITHNORIVIAL KARYOTYPE," the entire contents of which are incorporated by reference included in this application. technical field [0003] Some embodiments provided herein relate to methods and compositions for reducing the risk of relapse of a hyperproliferative disorder such as acute myeloid leukemia (AML) in a subject, wherein the hyperproliferative cells of the subject exhibit a normal karyotype, and / or the subject The subjects have been administered no more than one course of induction chemotherapy. Some such embodiments include administering a NOX2 inhibitor such as histamine dihydrochloride (HDC) in combination with a cytokine such as interleukin-2 (IL-2). Background technique [0004] Hyperproliferative disorders encompass a wide ra...

AI Technical Summary

Problems solved by technology

However, as many as 60% or more of adult patients will relapse with leukemia within 2-3 years, with a poor prognosis for long-term survival

Images